AR041191A1 - Ligandos del receptor vanilloide y su uso en tratamientos - Google Patents

Ligandos del receptor vanilloide y su uso en tratamientos

Info

Publication number
AR041191A1
AR041191A1 ARP030102863A ARP030102863A AR041191A1 AR 041191 A1 AR041191 A1 AR 041191A1 AR P030102863 A ARP030102863 A AR P030102863A AR P030102863 A ARP030102863 A AR P030102863A AR 041191 A1 AR041191 A1 AR 041191A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
nrara
substituents
independently selected
Prior art date
Application number
ARP030102863A
Other languages
English (en)
Inventor
Partha P Chakravarty
An Mei Chen
Elizabeth M Doherty
Celia Dominguez
Jim Falsey
Christopher H Fotsch
Christopher Hulme
Jodie Katon
Thomas Nikey
Mark Henry Norman
Vassil I Ognyanov
Liping Pettus
Robert Rzasa
Markian Stec
Hui-Ling Wang
Jiawang Zhu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR041191A1 publication Critical patent/AR041191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos y composiciones que los contienen, para el tratamiento del dolor agudo, inflamatorio y neuropático, dolor de dientes, dolor general de cabeza, migrana, dolor de cabeza concentrado, síndromes vasculares mixtos y no vasculares, dolor de cabeza por tensión, inflamación general, artritis, enfermedades reumáticas, osteoartritis, desórdenes inflamatorios intestinales, desórdenes inflamatorios de los ojos, desórdenes inflamatorios o inestables de la vejiga, soriasis, afecciones de la piel con características inflamatorias, condiciones inflamatorias crónicas, dolor inflamatorio y alodinia e hiperalgesia asociadas, dolor neuropático alodinia e hiperalgesia asociadas, dolor neuropático diabético, causalgia, dolor mantenido por simpatía, sindromes de diferenciación, asma, disfunción o dano de tejido epitelial, herpes simple, desórdenes de motilidad visceral en regiones respiratorias, genitourinarias, gastrointestinales o vasculares, heridas, quemaduras, reacciones dérmicas alérgicas, prurito, vitiligo, desórdenes gastrointestinales generales, ulceración gástrica, úlceras duodenales, diarrea, lesiones gástricas provocadas por agentes necrotizantes, crecimiento de pelo, rinitis alérgica o vasomotora, desórdenes bronquiales o desórdenes de la vejiga. Reivindicación 1: Un compuesto que tiene la estructura (1); o una de sus sales farmacéuticamente aceptables, donde J es O ó S; X es =N- o =C(R2)-; Y es =N- o =C(R3)-, donde al menos uno de X e Y no es =N-; n es, independientemente, en cada instancia, 0, 1 o 2. R1 es de fórmula (2) o R1 es un naftilo substituido por 0, 1, 2 ó 3 substituyentes que se seleccionan independientemente de R5; o R1 es Rb substituido por 1, 2 ó 3 substituyentes que se seleccionan independientemente de R5; R2 es, independientemente, en cada instancia, R10, alquilo C1-8 substituido por 0, 1 ó 2 substituyentes que se seleccionan de R10, -(CH2)nfenilo substituido por 0, 1, 2 ó 3 substituyentes que se seleccionan independientemente de R10, o un heterociclo saturado o insaturado de cadena cerrada de 5 o 6 miembros, que contiene 1, 2 ó 3 heteroátomos que se seleccionan independientemente de N, S, y O, donde no más de 2 de los miembros de la cadena cerrada son O o S, donde el heterociclo está optativamente fusionado con una cadena cerrada fenilo, y la cadena cerrada fenilo fusionada o el heterociclo es substituido por 0, 1, 2 ó 3 substituyentes que se seleccionan independientemente de R10; R3 es, independientemente, en cada instancia, H, halo, -NH2, -Nhalquilo C1-3, -N(alquilo C1-3)2, o alquilo C1-3; donde, cuando X es =C(R2)- e Y es =C(R3)-, al menos uno de R2 y R3 es diferente de H; R4 es de fórmula (3), o R4 es un heterocilo saturado o insaturado de cadena cerrada de 5 o 6 miembros, que contiene 1, 2 ó 3 átomos que se seleccionan de O, N y S que opcionalmente está fusionado en forma adyacente con un puente saturado o insaturado de 3 o 4 átomos, que contiene 0, 1, 2 o3 átomos que se seleccionan de O, N y S mientras que los átomos restantes son carbono, en la medida en que la combinación de los átomos de O y S no sea mayor que 2, donde los átomos de carbono del heterociclo y el puente son substituidos por 0, 1, 2 o 3 substituyentes que se seleccionan independientemente de Re, haloalquilo C1-4, halo, nitro, ciano, oxo, -ORf, -S(=O)nRe, -Ohaloalquilo C1-4, -Oalquilo C2-6NRaRf, -Oalquilo C2-6ORf, -Oalquilo C1-6C(=O)ORe, -NRaRf, -NRahaloalquilo C1-4, -NRaalquilo C2-6NRaRf, -NRaalquilo C2-6ORf, -C(=O)Re, -C(=O)Re, -OC(=O)Re, -C(=O)NraRf y -NRaC(=O)Re; y los átomos de carbono insaturados pueden estar adicionalmente substituidos por =O; y cualquier átomo de nitrógeno disponible en el heterociclo y en el puente es substituido por H, alquilo C1-6ORf, Re, -alquilo C1-6NraRf, -alquilo C1-3C(=O)Ore, -alquilo C1-6C(=O)NraRf, -alquilo C1-3OC(=O)Re, -alquilo C1-3NraC(=O)Re, -C(=O)Rc o -alquilo C1-3Rc; o bien R4 es naftilo substituido por 1, 2 o 3 substituyentes que se seleccionan independientemente de haloalquilo C1-4, halo, nitro, ciano, -S(=O)nRe, -Ohaloalquilo C1-4, -Oalquilo C2-6NRaRf, -Oalquilo C2-6ORf, -Oalquilo C1-6C(=O)ORe, -NRahaloalquilo C1-4, -NRaalquilo C2-6NRaRf, -NRaalquilo C2-6ORf, -C(=O)Re, -C(=O)Re, -OC(=O)Re, -C(=O)NraRf; pero en ninguna instancia es R4 3,5-ditrifluorometilfenilo, 3-trifluorometil-4-fluorofenilo, -fenilalquilo C1-8, -fenil-o-alquilo C1-6, -fenil-NraRa o -fenil-N(Ra)C(=O)(alquilo C1-8); R5 es, independientemente, en cada instancia, Rf, Rg, halo, nitro, ciano, -ORe, -ORg, -Oalquilo C2-6NRaRf, -Oalquilo C2-6ORf, -NRaRf, -NRaRg, -NRfC2 6alquiloNRaRf, -NRfalquilo C2-6ORf, naftilo,-CO2Re, -C(=O)Re, -C(=O)NRaRf, -C(=O)NRaRg, -NRfC(=O)Re, -NRfC(=O)Rg, -NRfC(=O)NRaRf, -NRfCO2Re, -alquilo C1-8ORf, -alquilo C1-6NRaRf, -S(=O)nRe, -S(=O)2NRaRf, -NRaS(=O)2Re y -OC(=O)NRaRf, una cadena cerrada fenilo substituida con 0, 1, 2 o 3 substituyentes que se seleccionan independientemente de R10; o bien R5 es un heterociclo saturado o insaturado de cadena cerrada de 5 a 6 miembros, que contiene 1, 2 o 3 átomos que se seleccionan de O, N y S substituido con 0, 1, 2 o 3 substituyentes que se seleccionan independientemente de R10; R6 es independientemente, en cada instancia, H, C1-5alquilo, haloalquilo C1-4, halo, -Oalquilo C1-6, -Ohaloalquilo C1-4, -Oalquilo C2-6NRaRa, -Oalquilo C2-6ORa, -NRaRa, -NRahaloalquilo C1-4, - NRaalquilo C2-6NRaRa o -NRaalquilo C2-6ORa, -alquilo C1-8ORa, -alquilo C1-6NRaRa, -S(alquilo C1-6), una cadena cerrada fenilo substituida con 1, 2, o 3 substituyentes que se seleccionan independientemente de R10; o R6 es un heterociclo saturado o insaturado de cadena cerrada de 5 o 6 miembros que contiene 1, 2 o 3 átomos que se seleccionan de O, N y S substituido con 0, 1, 2, o 3 substituyentes que se seleccionan independientemente de R10; R7 es independientemente, en cada instancia, H, alquilo C1-8, haloalquilo C1-4, halo, ciano, -Oalquilo C1-6, -Ohaloalquilo C1-4, -Oalquilo C2-6NRaRa, -Oalquilo C2-6ORa, -NRaRa, -NRahaloalquilo C1-4, -NRaalquilo C2-6NRaRa, -NRaalquilo C2-6ORa, -alquilo C1-8ORa, -alquilo C1-6NRaRa o -S(alquilo C1-6); o es un heterociclo saturado o insaturado de cadena cerrada de 4 o 5 miembros, que contiene un único átomo de nitrógeno, donde la cadena cerrada es substituida con 0, 1 o 2 substituyentes que se seleccionan independientemente de halo, C1-2haloalquilo y alquilo C1-3; R8 es independientemente, en cada instancia, H, C1-5alquilo, haloalquilo C1-4, halo, -Oalquilo C1-6, -Ohaloalquilo C1-4, -Oalquilo C2-6NRaRa, -Oalquilo C2-6ORa, -NRaRa, - NRahaloalquilo C1-4, -NRaalquilo C2-6NRaRa, -NRaalquilo C2-6ORa, -alquilo C1-8ORa, -alquilo C1-6NRaRa, -S(alquilo C1-6), una cadena cerrada fenilo substituida con 1, 2, o 3 substituyentes que se seleccionan independientemente de R10, o bien R8 es un heterociclo saturado o insaturado de cadena cerrada de 5 o 6 miembros que contiene 1, 2 o 3 átomos que se seleccionan de O, N y S substituido con 0,1, 2, o 3 substituyentes que se seleccionan independientemente de R10; R9 es independientemente,en cada instancia, Rf, Rg, halo, nitro, ciano, -ORe, -ORg, -Oalquilo C2-6NRaRf, -Oalquilo C2-6ORf, -NRaRf, -NRaRg, -NRfalquilo C2-6NRaRf, - NRfalquilo C2-6ORf, naftilo,-CO2Re, -OC(=O)Re, -C(=O)Re, -C(=O)NRaRf, -C(=O)NRaRg, -NRfC(=O)Re, -NRfC(=O)Rg, -NRfC(=O)NRaRf, -NRfCO2Re, -alquilo C1-8ORf, -alquilo C1-6NRaRf, -S(=O)nRe, -S(=O)2NRaRf, -NRaS(=O)2Re, -OC(=O)NRaRf, una cadena cerrada fenilo substituida con 1, 2, o 3 substituyentes que se seleccionan independientemente de R10, o bien R9 es un heterociclo saturado o insaturado de cadena cerrada de 5 o 6 miembros que contiene 1, 2 o 3 átomos que se seleccionan de O, N y S substituido con 0,1, 2, o 3 substituyentes que se seleccionan independientemente de R10; o bien R9 es un heterociclo saturado o insaturado de cadena cerrada de 4 o 5 miembros que contiene un único átomo de nitrógeno, donde la cadena cerrada está substituida con 1, 2 o 3 substituyentes que se seleccionan independientemente de halo, haloalquilo C1-2 y alquilo C1-3; donde al menos uno de R5, R6, R7, R8 y R9 es alquilo C1-8, haloalquilo C1-4, halo, -Ohaloalquilo C1-4, -Oalquilo C2-6NRaRa, -Oalquilo C2-6ORa, -NRahaloalquilo C1-4, -NRaalquilo C2-6NRaRa, -NRaalquilo C2-6ORa, -alquilo C1-8ORa, -alquilo C1-6NRaRa o -S(alquilo C1-6);R10 independientemente, en cada instancia, se selecciona de H, alquilo C1-8, haloalquilo C1-4, halo, ciano, nitro, -C(=O)(alquilo C1-8), -C(=O)O(alquilo C1-8), -C(=O)NraRa, -C(NRa)NraRa, -Ora, -OC(=O)(alquilo C1-8), -OC(=O)NraRa, -OC(=O)N(Ra)S(=O)2(alquilo C1-8), -Oalquilo C2-6NraRa, -Oalquilo C2-6Ora, -SRa, -S(=O)(alquilo C1-8), -S(=O)2(alquilo C1-8), -S(=O)2NraRa, -S(=O)2NraC(=O)(alquilo C1-8), -S(=O)2NraC(=O)O(alquilo C1-8), -S(=O)2NraC(=O) NraRa, -NraRa, -N(ra)C(=O)(alquilo C1-8), -N(ra)C(=O)O(alquilo C1-8), -N(ra)C(=O)NraRa, -N(ra)C(=Nra)NraRa, -N(ra)S(=O)2(alquilo C1-8), -N(ra)S(=O)2NraRa, -NRaalquilo C2-6NraRa y -NRaalquilo C2-6ORa; o R10 es una cadena cerrada saturada o insaturada monocíclica de 5, 6 o 7 miembros o bicíclica de 6, 7, 8, 9, 10 u 11-miembros que contiene 1, 2 o 3 átomos que se seleccionan de O, N y S, donde hay no más de 2 átomos de N, y donde la cadena cerrada está fusionada con 0 o 1 grupo benzo y 0 o 1 cadena cerrada heterocíclica, saturada o insaturada, de 5, 6 o 7 miembros que contiene 1, 2 o 3 átomos que se seleccionan de O, N y S; donde los átomos de carbono de la cadena cerrada son substituidos por 0, 1 o 2 grupos oxo, donde la cadena cerrada es substituida por 1, 2 o 3 grupos que se seleccionan de alquilo C1-8, haloalquilo C1-4, halo, ciano, nitro, -C(=O)(alquilo C1-8), -C(=O)O(alquilo C1-8), -C(=O)NraRa, -C(NRa)NraRa, -Ora, -OC(=O)(alquilo C1-8), -OC(=O)NraRa, -OC(=O)N(Ra)S(=O)2(alquilo C1-8), -Oalquilo C2-6NraRa, -Oalquilo C2-6Ora, -SRa, -S(=O)(alquilo C1-8), -S(=O)2(alquilo C1-8), -S(=O)2NraRa, -S(=O)2NraC(=O)(alquilo C1-8), -S(=O)2NraC(=O)O(alquilo C1-8), -S(=O)2NraC(=O)NraRa, -NraRa, -N(ra)C(=O)(alquilo C1-8), -N(ra)C(=O)O(alquilo C1-8), -N(ra)C(=O)NraRa, -N(ra)C(=Nra)NraRa, -N
ARP030102863A 2002-08-08 2003-08-08 Ligandos del receptor vanilloide y su uso en tratamientos AR041191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40242202P 2002-08-08 2002-08-08

Publications (1)

Publication Number Publication Date
AR041191A1 true AR041191A1 (es) 2005-05-04

Family

ID=31715852

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102863A AR041191A1 (es) 2002-08-08 2003-08-08 Ligandos del receptor vanilloide y su uso en tratamientos

Country Status (19)

Country Link
US (3) US7144888B2 (es)
EP (3) EP1717220A3 (es)
JP (1) JP4555082B2 (es)
KR (1) KR20050055694A (es)
CN (1) CN1694873A (es)
AR (1) AR041191A1 (es)
AU (2) AU2003264047B2 (es)
BR (1) BR0313255A (es)
CA (1) CA2493667C (es)
EA (1) EA010380B1 (es)
IL (1) IL166396A0 (es)
MX (1) MXPA05001456A (es)
NO (1) NO20051193L (es)
NZ (1) NZ537952A (es)
PL (1) PL376372A1 (es)
RS (1) RS20050161A (es)
TW (1) TW200410945A (es)
WO (1) WO2004014871A1 (es)
ZA (1) ZA200501332B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) * 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2532971A1 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2556239A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034446A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006089311A1 (en) * 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2006236387A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
WO2006124753A2 (en) * 2005-05-12 2006-11-23 Amgen Inc. Antipyretic agents against vr1-antagonist-induced increases in body temperature
EP2540296A1 (en) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
AU2006311910A1 (en) * 2005-11-03 2007-05-18 Irm Llc Protein kinase inhibitors
US7709501B2 (en) * 2005-12-23 2010-05-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
DE102006008880A1 (de) * 2006-02-27 2007-09-06 Merck Patent Gmbh Aminopyrimidinderivate
EP2010528B1 (en) 2006-04-19 2017-10-04 Novartis AG 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
CA2662754A1 (en) * 2006-08-22 2008-02-28 Amgen Inc. Sorbic acid analog co-crystals
KR101503286B1 (ko) 2006-12-15 2015-03-17 얀센 파마슈티카 엔.브이. 벤즈이미다졸 ｔｒｐｖ1 저해제
CN101925575B (zh) 2008-01-28 2014-06-18 株式会社爱茉莉太平洋 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物
JP5372138B2 (ja) 2008-04-18 2013-12-18 テウン ファーマシューティカル カンパニー，リミテッド 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2307394B1 (en) 2008-07-02 2012-09-26 Amorepacific Corporation Sulphonamides as vanilloid receptor antagonist
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US7737157B2 (en) * 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
WO2010070022A1 (de) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Neue verbindungen
CN102361863B (zh) 2009-01-21 2014-12-03 巴斯利尔药物股份公司 新的二环抗生素
JP5894540B2 (ja) 2010-02-18 2016-03-30 ブイティーブイ・セラピューティクス・エルエルシー フェニル−ヘテロアリール誘導体とその使用の方法
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
CN102020647B (zh) * 2010-11-18 2013-09-11 孙智华 1-(2,2-二氟乙氧基)-6-三氟甲基-n-([1,2,4]三氮唑[1,5-c]嘧啶-2-)苯磺酰胺的制备方法
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
WO2013175415A1 (en) * 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
KR20170122782A (ko) * 2015-02-27 2017-11-06 난트바이오사이언스 인코포레이티드 키나아제 억제제로서의 피리미딘 유도체 및 그 치료적 용도
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
KR101983788B1 (ko) * 2016-12-01 2019-05-30 서울대학교산학협력단 아미드 유도체 화합물, 이의 입체이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 피부 노화 억제, 주름 개선, 또는 피부 상처 치료용 약학적 또는 화장료 조성물
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR102039608B1 (ko) 2017-11-03 2019-11-01 주식회사 셀버틱스 미도드린을 포함하는 조성물 및 이의 용도
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
WO2024083237A1 (en) * 2022-10-20 2024-04-25 Impact Therapeutics (Shanghai) , Inc Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940395A (en) * 1969-08-29 1976-02-24 American Home Products Corporation 4-Amino-2-phenyl-6-thiopryimidines
JPS54115384A (en) * 1978-02-28 1979-09-07 Hokko Chem Ind Co Ltd Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB8417852D0 (en) * 1984-07-13 1984-08-15 Fujisawa Pharmaceutical Co Pyrimidine derivatives
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
US5750532A (en) * 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
US5272167A (en) * 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
KR930702312A (ko) 1990-08-31 1993-09-08 아만 히데아키 피리미딘 유도체 및 의약
IL118469A (en) * 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
IL122670A0 (en) 1995-06-20 1998-08-16 Du Pont Arthropodicidal and fungicidal cyclic amides
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
CA2252701C (en) 1996-05-01 2003-10-28 Mississippi State University Halo-substituted protein kinase c inhibitors
US5959123A (en) * 1996-09-23 1999-09-28 Synphar Laboratories, Inc. 3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
US5916887A (en) * 1996-09-23 1999-06-29 National Research Council Of Canada 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
AU5463398A (en) 1996-11-26 1998-06-22 E.I. Du Pont De Nemours And Company Methyl substituted fungicides and arthropodicides
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
US5932590A (en) * 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6093737A (en) * 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998028980A1 (en) 1996-12-30 1998-07-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP4444493B2 (ja) 1997-08-20 2010-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア カプサイシン受容体およびカプサイシン受容体関連ポリペプチドをコードする核酸配列ならびにその使用
BR9812041B1 (pt) 1997-09-05 2009-08-11 processo para a preparação de derivados n-acilados (hetero) aromáticos da hidroxilamina.
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
CA2321218A1 (fr) 1998-02-13 1999-08-19 Aventis Pharma S.A. Derives de systemes heterocycliques condenses, leur preparation, les compositions pharmaceutiques qui les contiennent
US6306866B1 (en) * 1998-03-06 2001-10-23 American Cyanamid Company Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
PT1107965E (pt) * 1998-08-25 2004-10-29 Ortho Mcneil Pharm Inc Eteres e tioeteres de piridilo como ligantes para receptores de acetilcolina nicotinica e as suas aplicacoes terapeuticas
US6127376A (en) * 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
YU59801A (sh) * 1999-02-24 2005-07-19 F. Hoffmann-La Roche Ag. Fenil- i piridinil-derivati
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
GB9907683D0 (en) * 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1219606A4 (en) 1999-07-19 2005-08-31 Shionogi & Co ACYLOXYMETHOXYCARBONYLE PENDANT TRICYCLIC COMPOUNDS
AU6016000A (en) 1999-07-23 2001-02-13 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
CN1364080A (zh) 1999-07-23 2002-08-14 盐野义制药株式会社 Th2分化抑制剂
WO2001014331A2 (en) 1999-08-24 2001-03-01 Regents Of The University Of California Non-quinoline inhibitors of malaria parasites
JP2003529547A (ja) 1999-09-14 2003-10-07 アボット・ラボラトリーズ 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
JP2003509507A (ja) 1999-09-21 2003-03-11 キネティック リミテッド 液晶化合物
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
ID30204A (id) * 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
IL150632A0 (en) 2000-01-18 2003-02-12 Pfizer Prod Inc Corticotropin releasing factor antagonists
AU2001231202A1 (en) 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives
GB0005789D0 (en) 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
KR20030009416A (ko) 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 고지용성 약물을 함유하는 유성 조성물
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
BR0113633A (pt) 2000-08-30 2005-06-07 Dow Agrosciences Llc Compostos úteis como inseticidas, compostos úteis como acaricidas e processos para utilização e obtenção dos mesmos
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
ES2318649T3 (es) * 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
AU2002224942A1 (en) 2000-12-20 2002-07-01 Syngenta Participations Ag N-acyl aminoacetonitriles having pesticidal properties
ES2292753T4 (es) 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
US6790845B2 (en) 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
EP1389616B1 (en) 2001-04-27 2011-07-27 Mitsubishi Tanabe Pharma Corporation 3,4-Dihalobenzylpiperidine derivatives and their medical use
JP2003212846A (ja) * 2001-06-26 2003-07-30 Japan Tobacco Inc 縮合環化合物及びｃ型肝炎治療剤
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
JP2005509606A (ja) 2001-10-03 2005-04-14 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ
EP1432687A2 (en) 2001-10-03 2004-06-30 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
DE60226756D1 (de) 2001-10-04 2008-07-03 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
EP1446115B1 (en) 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
WO2003049702A2 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200406374A (en) * 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
US7148221B2 (en) 2006-12-12
NZ537952A (en) 2008-04-30
CA2493667A1 (en) 2004-02-19
TW200410945A (en) 2004-07-01
IL166396A0 (en) 2006-01-15
BR0313255A (pt) 2005-07-12
PL376372A1 (en) 2005-12-27
CN1694873A (zh) 2005-11-09
EA200500168A1 (ru) 2005-08-25
US7332511B2 (en) 2008-02-19
JP2006504670A (ja) 2006-02-09
CA2493667C (en) 2010-04-27
EP2270006A1 (en) 2011-01-05
NO20051193L (no) 2005-05-04
ZA200501332B (en) 2007-04-25
KR20050055694A (ko) 2005-06-13
AU2003264047A1 (en) 2004-02-25
US20050272777A1 (en) 2005-12-08
WO2004014871A1 (en) 2004-02-19
JP4555082B2 (ja) 2010-09-29
AU2003264047B2 (en) 2008-06-26
WO2004014871A8 (en) 2005-04-07
EP1717220A3 (en) 2007-08-22
US20050277631A1 (en) 2005-12-15
AU2008202517A1 (en) 2008-06-26
US20040082780A1 (en) 2004-04-29
EP1717220A2 (en) 2006-11-02
MXPA05001456A (es) 2005-06-06
EP1546116A1 (en) 2005-06-29
EA010380B1 (ru) 2008-08-29
RS20050161A (en) 2007-09-21
US7144888B2 (en) 2006-12-05

Similar Documents

Publication Publication Date Title
AR041191A1 (es) Ligandos del receptor vanilloide y su uso en tratamientos
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
DE60309863D1 (de) S-kristalline polypropylene
ECSP034534A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
CO4700433A1 (es) Nuevas sulfonamidas heterociclicas oxigenadas inhibidoras de la proteasa aspartilo
AR002244A1 (es) Nuevos derivados de [3-(4-fenilpiperacin-1-il)propilamino]-piridina y benceno como antagonistas de ó 1-andrenoceptores, una composicion farmaceuticaque los contiene, un procedimiento para su preparacion y empleo de los mismos.
ATE394100T1 (de) Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthalten
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4
ES2087625T3 (es) Derivados de ciclohexano sustituidos, procedimiento para su preparacion y el empleo de los compuestos para el tratamiento de enfermedades.
AR037620A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, procedimientos para su preparacion, su utilizacion como medicamento y medicamento que las contiene
AR035727A1 (es) Compuestos macrolido-esteroides o macrolido no-esteroide, sus sales y solvatos, su uso y procedimiento para su preparacion
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
AR035465A1 (es) Compuestos de imidazopiridina, procesos para su preparacion,formulacion farmaceutica, usos de estos compuestos para la fabricacion de medicamentos e intermediarios
ES2202156T3 (es) Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.
CO5150190A1 (es) Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f
AR032622A1 (es) Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos
DE69510338D1 (de) Azirdin-derivate, deren herstellung und verwendung
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2
PE20001052A1 (es) Inhibidores de hiv proteasa
AR039445A1 (es) Derivados de pirazina sustituida y su uso
AR003932A1 (es) Oxidiazoles procineticos, su uso como medicamento, una composicion farmaceutica que los contiene, un procedimiento para preparar dicha composicion
AR037140A1 (es) Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende
ES2094048T3 (es) N-acilpirrolidinas y medicamentos para el tratamiento o la prevencion de los desordenes relacionados con la colecistoquinina y la gastrina.
FI935867A (fi) Tetrahydrobensazepinderivat som inhibiterar lipoxigenas

Legal Events

Date Code Title Description
FB Suspension of granting procedure